Insider Transactions in Q2 2025 at Artiva Biotherapeutics, Inc. (RTVA)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Christopher Horan Chief Tech Operations Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,341
-1.58%
|
$2,682
$2.13 P/Share
|
|
May 15
2025
|
Jennifer Bush COO, CLO, Secy, Compliance Off |
SELL
Payment of exercise price or tax liability
|
Direct |
1,937
-1.21%
|
$3,874
$2.13 P/Share
|
|
May 15
2025
|
Neha Krishnamohan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,341
-1.22%
|
$2,682
$2.13 P/Share
|
|
May 15
2025
|
Heather Raymon SVP, Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
745
-1.72%
|
$1,490
$2.13 P/Share
|
|
May 15
2025
|
Fred Aslan President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,472
-1.07%
|
$8,944
$2.13 P/Share
|
|
Apr 08
2025
|
Subhashis Banerjee Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|